Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JASON B FLEMING and HUAMIN WANG.
JASON B FLEMING
Connection Strength
3.707
HUAMIN WANG
  1. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22.
    View in: PubMed
    Score: 0.133
  2. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Lab Invest. 2015 Feb; 95(2):207-22.
    View in: PubMed
    Score: 0.129
  3. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Phys Biol. 2014 Nov 26; 11(6):065002.
    View in: PubMed
    Score: 0.129
  4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015 Apr; 22(4):1168-75.
    View in: PubMed
    Score: 0.128
  5. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin Cancer Res. 2014 Dec 15; 20(24):6529-40.
    View in: PubMed
    Score: 0.128
  6. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.122
  7. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23.
    View in: PubMed
    Score: 0.121
  8. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26.
    View in: PubMed
    Score: 0.119
  9. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Hum Pathol. 2014 Mar; 45(3):456-63.
    View in: PubMed
    Score: 0.119
  10. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8.
    View in: PubMed
    Score: 0.119
  11. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology. 2013 Dec; 63(6):841-51.
    View in: PubMed
    Score: 0.118
  12. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Jun; 44(6):1024-30.
    View in: PubMed
    Score: 0.112
  13. Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. Histopathology. 2013 Feb; 62(3):465-71.
    View in: PubMed
    Score: 0.112
  14. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Aug; 21(8):1336-43.
    View in: PubMed
    Score: 0.108
  15. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. Am J Surg Pathol. 2012 Apr; 36(4):552-9.
    View in: PubMed
    Score: 0.107
  16. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.106
  17. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.105
  18. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.104
  19. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012 Jan; 16(1):29-37.
    View in: PubMed
    Score: 0.104
  20. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012 Jun 15; 118(12):3182-90.
    View in: PubMed
    Score: 0.104
  21. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.102
  22. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol. 2012 Jul; 19 Suppl 3:S395-403.
    View in: PubMed
    Score: 0.101
  23. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011 Feb 15; 117(4):734-43.
    View in: PubMed
    Score: 0.096
  24. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2598-604.
    View in: PubMed
    Score: 0.096
  25. High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2010 Jul 15; 16(14):3734-42.
    View in: PubMed
    Score: 0.095
  26. Metastatic adult granulosa cell tumor mimicking a benign pancreatic cyst. Ann Diagn Pathol. 2010 Dec; 14(6):457-60.
    View in: PubMed
    Score: 0.092
  27. Current diagnosis and management of unusual pancreatic tumors. Am J Surg. 2008 Jul; 196(1):100-13.
    View in: PubMed
    Score: 0.082
  28. Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach. J Am Coll Surg. 2008 Jul; 207(1):106-20.
    View in: PubMed
    Score: 0.081
  29. Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. JOP. 2008 Jan 08; 9(1):56-60.
    View in: PubMed
    Score: 0.080
  30. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.034
  31. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.033
  32. SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium. PLoS One. 2014; 9(9):e107948.
    View in: PubMed
    Score: 0.032
  33. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. 2014; 9(7):e101452.
    View in: PubMed
    Score: 0.031
  34. Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. Am J Surg Pathol. 2014 Feb; 38(2):147-57.
    View in: PubMed
    Score: 0.030
  35. CT imaging features of acinar cell carcinoma and its hepatic metastases. Abdom Imaging. 2013 Dec; 38(6):1383-90.
    View in: PubMed
    Score: 0.030
  36. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.030
  37. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.030
  38. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.029
  39. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology. 2013 Dec; 145(6):1449-58.
    View in: PubMed
    Score: 0.029
  40. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res. 2013 Feb 01; 19(3):549-59.
    View in: PubMed
    Score: 0.028
  41. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.027
  42. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 01; 118(23):5749-56.
    View in: PubMed
    Score: 0.027
  43. KrasG12D-induced IKK2/?/NF-?B activation by IL-1a and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012 Jan 17; 21(1):105-20.
    View in: PubMed
    Score: 0.026
  44. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011; 6(6):e20636.
    View in: PubMed
    Score: 0.025
  45. Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter. Proc Natl Acad Sci U S A. 2010 Aug 24; 107(34):15193-8.
    View in: PubMed
    Score: 0.024
  46. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
    View in: PubMed
    Score: 0.023
  47. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009; 4(11):1670-80.
    View in: PubMed
    Score: 0.023
  48. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009 Apr; 16(4):836-47.
    View in: PubMed
    Score: 0.021
  49. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008 May; 15(5):1356-66.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.